Peer Review History

Original SubmissionJanuary 30, 2022
Decision Letter - Arturo Cesaro, Editor

PONE-D-22-02948Lipid abnormalities and associated risk factors among HIV/AIDS patients on HAART in Asmara, EritreaPLOS ONE

Dear Dr. Kesete,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 04 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Arturo Cesaro, MD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section

Additional Editor Comments (if provided):

You are invited to consider the reviewers' comments, reported at the end of this letter, and to revise your manuscript accordingly. In the letter accompanying your resubmission, please explain your response to each of the comments. Please observe the word count and citation style. For further details, please consult the Instructions for Authors on the website

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Review comments

Title: Lipid abnormalities and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea

Submission ID: PONE-D-22-02948

The authors assess dyslipidemia associated with HAART in HIV/AIDS patients which an important topic to uncover the negative impacts of the treatment. So far, many studies elucidated this scenario and I appreciate the novelty of this study conducted in Eritrea for the first time. The point by point concerns are detailed below.

Title: the title better be “Dyslipidemia…..

Abstract:

Acronyms like HAART, LDL, TC, CVD, etc… should be fully written on their first appearance

In the results section, CD4 should be corrected as “CD4+ T cell count (cell/microliter)”. In addition, results with a significant association at aOR should be considered the real predictors. cOR data cannot be inferred or reported as final outcome of association

In the conclusion factors significantly associated with dyslipidemia should be highlighted

Results

In the results, the cOR values better be displayed for readers convenience

Discussion

Subtitles in the discussion could be removed. Besides, the limitations of the study should be stated at the last paragraph of the discussion. Then the importance of the study can be mentions

Conclusion

The conclusion should not contain results values like percentages. The conclusion should be a single paragraph containing the burden of dyslipidemia (not in percentages, rather saying either “significantly high” or other means of expression). Then important predictors are mentioned and lastly a brief recommendation should be included.

Reviewer #2: Dear Authors, thank you for your work. The data are interesting but are presented in an unclear way. The text is very difficult to read, especially the presentation of the results. Furthermore, there are long and repetitive sections within the methods with not important data while some fundamental aspects are totally absent, such as the timing of the collection of the lipid profile in these patients.

1) At what time of HAART therapy were the patients evaluated for lipid profile?

2) Do we have baseline or pre-therapy values ​​in at least some of the patients?

3) Furthermore, the therapy taken by patients should be better analyzed, looking for the use of statins in at least part of them.

4) A complete revision of the English language by native speakers is extremely necessary.

5) There are also widespread grammatical errors and typos.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: HYLEMARIAM MIHIRETIE MENGIST

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachments
Attachment
Submitted filename: Review comments.docx
Revision 1

Rebuttal Letter: Response to Reviewers

Reviewer 1

1. Abbreviation issues: Acronyms like HAART, LDL, TC, CVD, etc… should be fully written on their first appearance. DONE.

All acronyms that has been mentioned in the study are written in full in their first mention.

2. In the results section, CD4 should be corrected as “CD4+ T cell count (cell/microliter)”.

“CD4” has now been corrected as “CD4+ T cell count (cell/microliter)” in the revised manuscript.

3. Results with a significant association at aOR should be considered the real predictors not cOR data.

General frequencies and the key risk factors which have showed significant association in multivariate regression analysis are indicated in the abstract section. Similar approach has also implemented in the conclusion section.

4. In the results, the cOR values better be displayed for readers convenience.

Univariate regression analysis table is now included in the manuscript.

5. In the conclusion, factors significantly associated with dyslipidemia should be highlighted.

The main risk factors that have been revealed statistically are outlined in the conclusion section. Necessary interventional recommendation have also been included.

6. Subtitles in the discussion could be removed.

The discussion section is now summarized under one title detailing about all the prevalence, effect of drug regimens and factors associated with dyslipidemia.

7. The limitations of the study should be stated at the last paragraph of the discussion. Then the importance of the study can be mentions.

The last paragraph of the discussion section is rewritten according the reviewers guide.

8. The conclusion should be a single paragraph without result values like percentages and showing burden of dyslipidemia in other means of expression.

- The conclusion is formatted now in one paragraph showing the key findings of the study and other important predictors. A brief recommendation is also included in the last lines of the paragraph.

Reviewer 2

9. There are long and repetitive sections within the methods with not important data.

The methods part is now summarized and details on inclusion criteria, data collection have been revised to indicate the key information regarding study participants.

10. At what time of HAART therapy were the patients evaluated for lipid profile?

At the time of blood sampling, the duration of HAART use in the patients ranged from 1 year to 16 years. The mean duration of HAART use was 4.57(±2.43) years. The prevalence of dyslipidemia worsens across time after ART initiation, despite initial favorable changes in TG and HDL during the 6 months period. To minimize this apparent effect in this study, only patients who had HAART for more than one year were included.

This has been explained in the second paragraph of the results portion.

11. Do we have baseline or pre-therapy values ​​in at least some of the patients?

Due to the cross sectional nature of the study, lipid profile assessments were conducted during the therapy time. Currently, evaluation of fat levels in HIV patients in Eritrea is not a regular package of the pre-therapy investigations like CD4 count, viral load, kidney function and blood sugar. Some few patients may have lipid profile tests during first stages of therapy period by specific physician order to evaluate complications related to the disease.

One of the aim of this study is to include lipid profile tests in all HIV patients immediately before the initiation of HAART treatment and to sustain its continuous examination during therapy. This have been outlined at the last paragraph of the conclusion portion.

12. The therapy taken by patients should be better analyzed, looking for the use of statins in at least part of them.

All therapies including accessory drugs taken by patients for other complications related to the disease were assessed. Patients who were taking any lipid altering or anti-dyslipidemic drugs were primarily excluded from the study. These include statins like, but not limited to, atorvastatin, fluvastatin, lovastatin and rosuvastatin which are commonly prescribed in the study setting. Moreover, patients who were generally taking fibrates, bile acid sequestrants, niacin and ezetimibe were also excluded for their effect in altering lipid values in patients.

This has been indicated at the sampling technique and inclusion criteria subtitles of the methodology portion.

13. The text is very difficult to read, especially the presentation of the results. A complete revision is needed by native speakers. There are also widespread grammatical errors and typos.

The manuscript have been revised for spelling and typing errors. Moreover, the text have been overviewed by two English native speakers for grammatical issues. Portions which were not clear have been corrected in the revised manuscript.

Attachments
Attachment
Submitted filename: Responses to reviewers.pdf
Decision Letter - Arturo Cesaro, Editor

Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea

PONE-D-22-02948R1

Dear Dr. Kesete,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Arturo Cesaro, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The manuscript appears to be improved after editing in accordance with the reviewers' comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The significantly associated factors should be clearly indicated in the table. use either asterisks or other symbols.

Reviewer #2: Dear authors,

Thanks to have replied to my comments. I think that the text has been improved after revision

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: HYLEMARIAM MIHIRETIE MENGIST

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Arturo Cesaro, Editor

PONE-D-22-02948R1

Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea

Dear Dr. Kesete:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Arturo Cesaro

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .